FY2025 Earnings Forecast for Incyte Issued By William Blair

Incyte Co. (NASDAQ:INCY) – Research analysts at William Blair increased their FY2025 earnings per share (EPS) estimates for shares of Incyte in a research report issued to clients and investors on Tuesday, March 18th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $4.21 per share for the year, up from their prior estimate of $4.20. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%.

INCY has been the topic of a number of other reports. Guggenheim lowered Incyte from a “buy” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a report on Tuesday. Stifel Nicolaus upped their price objective on Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a report on Monday, February 10th. JMP Securities reaffirmed a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reduced their target price on Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Incyte has an average rating of “Hold” and an average target price of $75.13.

Incyte Stock Performance

Shares of NASDAQ INCY opened at $60.34 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The stock’s fifty day moving average price is $71.03 and its two-hundred day moving average price is $70.20. Incyte has a one year low of $50.35 and a one year high of $83.95. The firm has a market cap of $11.68 billion, a price-to-earnings ratio of 223.49, a P/E/G ratio of 0.41 and a beta of 0.76.

Hedge Funds Weigh In On Incyte

Large investors have recently bought and sold shares of the company. Quintet Private Bank Europe S.A. bought a new position in Incyte in the fourth quarter valued at about $26,000. Global X Japan Co. Ltd. raised its position in Incyte by 144.7% in the fourth quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 230 shares during the last quarter. R Squared Ltd bought a new position in Incyte in the fourth quarter valued at about $30,000. Brooklyn Investment Group bought a new position in Incyte in the third quarter valued at about $30,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Incyte in the third quarter valued at about $33,000. 96.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total transaction of $41,924.01. Following the completion of the sale, the executive vice president now directly owns 25,848 shares in the company, valued at $1,809,101.52. This represents a 2.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total value of $897,866.88. Following the sale, the executive vice president now owns 66,967 shares of the company’s stock, valued at approximately $4,867,831.23. This represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 46,827 shares of company stock worth $3,322,618 in the last ninety days. 17.60% of the stock is owned by insiders.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.